Biogen
About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Company Ownership: Public
Stock Symbol: BIIB
Stock Exchange: NASDAQ
At Biogen we are connected by a greater purpose to help improve the lives of patients, work fearlessly, and grow together. Hear from the best and brightest at Biogen on what inspires them every day and why you should join our team.
1901 articles about Biogen
-
Backing Away From Biotechs
2/14/2005
-
New Component Of The "Brakes" On Nerve Regeneration Found
2/3/2005
-
Big Pharma's Ails Could Spread To Biotech
1/27/2005
-
Biogen Idec Hunts For Local Hires
1/13/2005
-
Jacobs Restarts Work On Large-Scale Biologic Manufacturing Facility For Biogen Idec
1/6/2005
-
Biotech 2005: New Drugs Hold The Key
12/29/2004
-
The Day In Review: Biotech Up All Day
11/24/2004
-
Biotech Ready To Run
11/15/2004
-
The National MS Society, Biogen Idec, And MSWorld, Inc., Recognize Winners Of The First Annual MS Leaders Of Hope(SM)
11/12/2004
-
Biogen Idec, Inc. (Massachusetts) Reports Third Quarter 2004 Results
10/28/2004
-
Biogen Idec’s Breakthrough MS Drug
10/22/2004
-
Biotechnology Outpacing Pharmaceutical Growth
10/11/2004
-
Biogen Idec, Inc. (Massachusetts) To Present At The Bear Stearns 17th Annual Healthcare Conference
9/8/2004
-
Antegren Data Delay Raises Eyebrows
8/19/2004
-
Surviving Biotech's Downturns
8/18/2004
-
Biotech Cost Control
8/11/2004
-
Playing The High-Stakes Biotech Game
7/8/2004
-
Biogen Idec Forms Parkinson's Deal With Vernalis For $100M
6/30/2004
-
Top 2003 Stories From The BioSpace NewsBeat
12/31/2003
-
Biogen Idec, Inc. Release: Zevalin(R) (Ibritumomab Tiuxetan) Therapeutic Regimen Produces Long-Term Durable Remissions In Patients With Non-Hodgkin's Lymphoma
12/8/2003